Literature DB >> 31603413

Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019.

Sebastien J Hotte1, Anil Kapoor2,3, Naveen S Basappa4, Georg Bjarnason5, Christina Canil6, Henry J Conter7, Piotr Czaykowski8, Jeffrey Graham8, Samantha Gray9, Daniel Y C Heng10, Pierre I Karakiewicz11, Christian Kollmannsberger12, Aly-Khan A Lalani1, Scott A North4, François Patenaude13, Denis Soulières14, Phillippe Violette4, Eric Winquist15, Lori A Wood16, Shaan Dudani10, Ranjena Maloni3, M Neil Reaume6.   

Abstract

Entities:  

Year:  2019        PMID: 31603413      PMCID: PMC6788909          DOI: 10.5489/cuaj.6256

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  81 in total

1.  Management of kidney cancer: canadian kidney cancer forum consensus update 2011.

Authors:  Mas Jewett; A Finelli; C Kollmannsberger; L Wood; L Legere; J Basiuk; C Canil; D Heng; N Reaume; S Tanguay; M Atkins; G Bjarnason; J Dancey; M Evans; N Fleshner; M Haider; A Kapoor; R Uzzo; D Maskens; D Soulieres; G Yousef; N Basappa; N Bendali; P Black; N Blais; I Cagiannos; M Care; R Chow; H Chung; P Czaykowski; D Derosa; K Durrant; S Ellard; G Farquharson; C Filion-Brulotte; J Gingerich; L Godbout; R Grant; W Hamilton; W Kassouf; G Kurban; K Lane; Jb Lattouf; D Lau; M Leveridge; J McCarthy; R Moore; S North; P O'brien; E Pituskin; P Racine; R Rendon; A So; S Sridhar; K Stubbs; Z Su; L Taylor; T Udall; P Venner; W Vogel; S Yap; P Yau; M Cooper; N Giroux; D Miron; D Mosher; K Ross; J Willacy
Journal:  Can Urol Assoc J       Date:  2012-02       Impact factor: 1.862

2.  Pseudoprogression and Immune-Related Response in Solid Tumors.

Authors:  Victoria L Chiou; Mauricio Burotto
Journal:  J Clin Oncol       Date:  2015-08-10       Impact factor: 44.544

3.  Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.

Authors:  Robert J Motzer; Thomas E Hutson; Hilary Glen; M Dror Michaelson; Ana Molina; Timothy Eisen; Jacek Jassem; Jakub Zolnierek; Jose Pablo Maroto; Begoña Mellado; Bohuslav Melichar; Jiri Tomasek; Alton Kremer; Han-Joo Kim; Karen Wood; Corina Dutcus; James Larkin
Journal:  Lancet Oncol       Date:  2015-10-22       Impact factor: 41.316

4.  Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.

Authors:  Alain Ravaud; Robert J Motzer; Hardev S Pandha; Daniel J George; Allan J Pantuck; Anup Patel; Yen-Hwa Chang; Bernard Escudier; Frede Donskov; Ahmed Magheli; Giacomo Carteni; Brigitte Laguerre; Piotr Tomczak; Jan Breza; Paola Gerletti; Mariajose Lechuga; Xun Lin; Jean-Francois Martini; Krishnan Ramaswamy; Michelle Casey; Michael Staehler; Jean-Jacques Patard
Journal:  N Engl J Med       Date:  2016-10-09       Impact factor: 91.245

5.  The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial.

Authors:  Georg A Bjarnason; Jennifer J Knox; Christian K Kollmannsberger; Denis Soulieres; D Scott Ernst; Pawel Zalewski; Christina M Canil; Eric Winquist; Sebastien J Hotte; Scott A North; Daniel Yick Chin Heng; Robyn Jane Macfarlane; Peter M Venner; Anil Kapoor; Aaron R Hansen; Bernhard J Eigl; Piotr Czaykowski; Ben Boyd; Lisa Wang; Naveen S Basappa
Journal:  Eur J Cancer       Date:  2019-01-14       Impact factor: 9.162

Review 6.  Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.

Authors:  Allan Lipton; Alejandro Colombo-Berra; Ronald M Bukowski; Lee Rosen; Ming Zheng; Gladys Urbanowitz
Journal:  Clin Cancer Res       Date:  2004-09-15       Impact factor: 12.531

7.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; David Cella; James Reeves; Robert Hawkins; Jun Guo; Paul Nathan; Michael Staehler; Paul de Souza; Jaime R Merchan; Ekaterini Boleti; Kate Fife; Jie Jin; Robert Jones; Hirotsugu Uemura; Ugo De Giorgi; Ulrika Harmenberg; Jinwan Wang; Cora N Sternberg; Keith Deen; Lauren McCann; Michelle D Hackshaw; Rocco Crescenzo; Lini N Pandite; Toni K Choueiri
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

8.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

9.  A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment.

Authors:  Mark Warren; Peter M Venner; Scott North; Tina Cheng; Chris Venner; Sunita Ghosh; Allison A Venner; Daygen Finch
Journal:  Can Urol Assoc J       Date:  2009-08       Impact factor: 1.862

10.  Management of advanced kidney cancer: Canadian Kidney Cancer Forum 2013 Consensus Update: Canadian Kidney Cancer Forum 2013.

Authors:  Scott North; Naveen Basappa; Georg Bjarnason; Normand Blais; Christina Canil; Daniel Heng; Jennifer Knox; Neil Reaume; Dean Ruether; Denis Soulières; Pawel Zalewski; Peter Black; Rodney H Breau; Rodney Breau; Michael Jewett; Anil Kapoor; Jean-Baptiste Lattouf; Ronald Moore; Ricardo Rendon; Gerald Todd; Edith Pituskin; Craig Gedye; Lori Wood
Journal:  Can Urol Assoc J       Date:  2013 Jul-Aug       Impact factor: 1.862

View more
  1 in total

Review 1.  Natural history of untreated kidney cancer.

Authors:  Kristen McAlpine; Antonio Finelli
Journal:  World J Urol       Date:  2021-02-16       Impact factor: 4.226

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.